Preview

Медицинский Совет

Расширенный поиск

СОВРЕМЕННЫЕ АСПЕКТЫ ЛЕЧЕНИЯ ЭНДОМЕТРИОЗА. ПРИМЕНЕНИЕ ДИЕНОГЕСТА

https://doi.org/10.21518/2079-701X-2017-13-54-56

Полный текст:

Аннотация

Диеногест – высокоэффективное средство для лечения основных болевых симптомов эндометриоза (хронической тазовой боли, диспареунии и дисменореи) и профилактики рецидива заболевания с высоким профилем безопасности и хорошей переносимостью, что позволяет назначать его с целью долгосрочной терапии заболевания. В пользу выбора именно указанного прогестагена свидетельствуют новейшие данные, отражающие всестороннее воздействие на различные звенья патогенеза заболевания.

Об авторах

Е. Г. Хилькевич
Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова Минздрава России
Россия

д.м.н.,

Москва



О. И. Лисицына
Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова Минздрава России
Россия
Москва


Список литературы

1. Begum T, Chowdhury SR. Aetiology and pathogenesis of endometriosis – a review. Mymensingh Med. J., 2013, 22(1): 218–21.

2. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis, Fertility and Sterility, 2012, 98(3): 511–519.

3. Giudice L, Kao L. Endometriosis. Lancet, 2004, 364(9447): 1789–99.

4. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obs. Gynecol Clin North Am., 1997, 24(2): 235–58.

5. The Practice Committee of the American Society of Reproductive Medicine, Treatment of pelvic pain associated with endometriosis: A committee opinion, Fertil. Steril., 2014, 101(4): 927–935.

6. Nnoaham KE, Hummelshoj L, Webster P,’Hooghe TD, De Cicco Nardone F, De Cicco Nardone C, Jenkinson C, Kennedy SH, Zondervan KT. Impact of endometriosis on quality of life and work productivity: A multicenter study across ten countries, Fertil. Steril., 2011, 96(2)6 366–373.e8.

7. Johnson NP, Hummelshoj L. Consensus on current management of endometriosis. Hum. Reprod., 2013, 28(6): 1552–1568.

8. Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills., Fertil. Steril., 2017, 107(3): 533–536.

9. Oettel M, Carol W, Elger W, Kaufmann G, Moore C, Romer W, Klinger G, Schneider B, Schroder J, Sobek L, Walter F, Zimmermann H. A 19-norprogestin without 17(alpha)-ethinyl group II: Dienogest from a pharmacodynamic point of view, Drugs of Today, 1995, 31(7): 517–36.

10. Klipping C, Duijkers I, TA F, SF K, Schuett B. Pharmacodynamic study of four oral dosages of dienogest. Fertility and Sterility, 2010, 94(suppl 1, 4): S181, Abstract P-304.

11. Чернуха Г.Е. Современные прогестагены в лечении эндометриоза (обзор международных исследований). Проблемы репродукции, 2012, 4: 68–71.

12. Yamanaka K, Xu B, Suganuma I, Kusuki I, Mita S, Shimizu Y, Mizuguchi K, Kitawaki J. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E 2 production in human endometriotic stromal cells in spheroid culture. Fertil. Steril., 2012, 97(2): 477–482.

13. Miyashita M, Koga K, Takamura M, Izumi G, Nagai M, Harada M, Hirata T, Hirota Y, Fujii T, Osuga Y. Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol. Endocrinol., 2014, 3590, 9: 1–5.

14. G R Attia, K Zeitoun, D Edwards, A Johns, B R Carr, and S E. Bulun, Progesterone receptor isoform A but not B is expressed in endometriosis. J. Clin. Endocrinol. Metab., 2000, 85(8): 2897–2902.

15. Hayashi A, Tanabe A, Kawabe S, Hayashi M, Yuguchi H, Yamashita Y, Okuda K, Ohmichi M. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J. Ovarian Res., 2012, 5(1): 31.

16. Grandi G, Mueller MD, Bersinger NA, Facchinetti F, McKinnon BD. The association between progestins, nuclear receptors expression and inflammation in endometrial stromal cells from women with endometriosis. Gynecol. Endocrinol., 2017, 0(0): 1–4.

17. Grandi G, Mueller M, Bersinger N, Papadia A, Nirgianakis K, Cagnacci A, McKinnon B. Progestin suppressed inflammation and cell viability of tumor necrosis factor-α-stimulated endometriotic stromal cells. Am. J. Reprod. Immunol., 2016, 76(4): 292–298.

18. Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A, McKinnon B. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm. Res., 2016, 65(3): 183–192.

19. Nirgianakis K, Grandi G, McKinnon B, Bersinger N, Cagnacci A, Mueller M. Dienogest mediates midkine suppression in endometriosis. Hum. Reprod., 2016, 31(9): 1981–1986.

20. Choi J, Jo M, Lee E, Lee DY, Choi D. Dienogest enhances autophagy induction in endometriotic cells by impairing activation of AKT, ERK1/2, and mTOR. Fertil. Steril., 2015, 104(3): 655–664.

21. Saito F, Tashiro H, Yamaguchi M, Honda R, Ohba T, Suzuki A, Katabuchi H. Development of a mouse model for testing therapeutic agents: The anticancer effect of dienogest on endometrial neoplasms. Gynecol. Endocrinol., 2016, 32(5): 403–407.

22. Takaesu Y, Nishi H, Kojima J, Sasaki T, Nagamitsu Y, Kato R, Isaka K. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis, J. Obstet. Gynaecol. Res., 2016, 42(9): 1152–1158.

23. Yamanaka A, Hada T, Matsumoto T, Kanno K, Shirane A, Yanai S, Nakajima S, Ebisawa K, Ota Y, Andou M. Effect of dienogest on pain and ovarian endometrioma occurrence after laparoscopic resection of uterosacral ligaments with deep infiltrating endometriosis, Eur. J. Obstet. Gynecol. Reprod. Biol., 2017, 216: 51–55.

24. Maiorana A, Incandela D, Parazzini F, Alio W, Mercurio A, Giambanco L, Alio L. Efficacy of dienogest in improving pain in women with endometriosis: a 12-month single-center experience. Arch. Gynecol. Obstet., 2017.

25. Park SY, Kim SH, Chae HD, Kim C-H, Kang BM. Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months, Clin. Exp. Reprod. Med., 2016, 43(4): 215.

26. Adachi K, Takahashi K, Nakamura K, Otake A, Sasamoto N, Miyoshi Y, Shioji M, Yamamoto Y, Fujitani M. Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas. Gynecol. Endocrinol., 2016, 32(8): 646–649.

27. Kim SA, Um MJ, Kim HK, Kim SJ, Moon SJ, Jung H. Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis. Obstet. Gynecol. Sci., 2016, 59(6): 506–511.

28. Доброхотова Ю.Э., Гришин И.Г., Ибрагимова Д.М., Нуруллин Р.Ф. Опыт применения Визанны у пациенток с диагностированным эндометриозом. Проблемы репродукции, 2014, 33–35.

29. Ярмолинская М.И., Беженарь В.Ф. Опыт применения диеногеста в комбинированном лечении генитального эндометриоза. Фарматека, 2013, 3: 48–51.

30. García Uranga-Romano A, Hernández-Valencia J, Zárate M, Basavilvazo-Rodríguez MA. Dienogest usefulness in pelvic pain due to endometriosis. A meta-analysis of its effectiveness. Rev Med Inst Mex Seguro Soc., 2017, 55(4) 452–455.


Просмотров: 115


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)